Case report of the dupilumab applying in atopic dermatitis child
- Authors: Revyakina V.A.1, Larkova I.A.1, Kuvshinova E.D.1, Mukhortykh V.A.1, Melnikova K.S.1
-
Affiliations:
- The Federal Research Center for Nutrition, Вiotechnology and Food Safety
- Issue: Vol 18, No 2 (2021)
- Pages: 115-122
- Section: Case reports
- URL: https://journals.rcsi.science/raj/article/view/121777
- DOI: https://doi.org/10.36691/RJA1424
- ID: 121777
Cite item
Abstract
In recent years, there has been a clear trend towards an increase in the number of patients with severe atopic dermatitis. In most cases, patients are dissatisfied with the previous therapy, which requires hospital treatment to relieve acute manifestations of atopic dermatitis and the selection of pharmacological agents aimed at achieving long-term control under the of the disease symptoms
The article presents the features of the atopic dermatitis therapy of at the present stage, the experience of using the new biological drug dupilumab in a 7-year-old child.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Vera A. Revyakina
The Federal Research Center for Nutrition, Вiotechnology and Food Safety
Author for correspondence.
Email: 5356797@mail.ru
ORCID iD: 0000-0002-1149-7927
SPIN-code: 4607-0540
MD, Dr. Sci. (Med.), Professor, Head of Allergy Department
Russian Federation, Moscow, 115445Inna A. Larkova
The Federal Research Center for Nutrition, Вiotechnology and Food Safety
Email: inna_larkova@mail.ru
ORCID iD: 0000-0001-7640-0754
SPIN-code: 2991-3774
MD, Cand. Sci. (Med.), Senior researcher of Allergy Department
Russian Federation, Moscow, 115445Elena D. Kuvshinova
The Federal Research Center for Nutrition, Вiotechnology and Food Safety
Email: len.kuwshinowa@yandex.ru
ORCID iD: 0000-0003-3650-6305
SPIN-code: 8403-2424
MD, Cand. Sci. (Med.), Senior Research Associate
Russian Federation, Moscow, 115445Valery A. Mukhortykh
The Federal Research Center for Nutrition, Вiotechnology and Food Safety
Email: valera-89@yandex.ru
ORCID iD: 0000-0001-8549-9493
SPIN-code: 3437-4081
Junior Research Associate
Russian Federation, Moscow, 115445Kseniya S. Melnikova
The Federal Research Center for Nutrition, Вiotechnology and Food Safety
Email: melnikova_ksenya85@bk.ru
ORCID iD: 0000-0002-6583-0545
Russian Federation, Moscow, 115445
References
- Allergology and Immunology: a national guide. Ed. by R.M. Khaitov, N.I. Ilyina. Moscow : GEOTAR-Media; 2009. 659 p. (In Russ).
- RAAKI. Russian Society of Dermatovenerologists and Cosmetologists (project). Atopic dermatitis. Clinical recommendations. Union of Pediatricians of Russia. 2020. (In Russ). Available from:https://raaci.ru/education/clinic_recomendations/100.html
- Kubanov AA, Bogdanova EV. Organization and results of medical care in the field of dermatovenerology in the Russian Federation. Results of 2018. Bulletin of Dermatology and Venereology. 2019;95(4):8–23. (In Russ). doi: 10.25208/0042-4609-2019-95-4-8-23
- Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. J Clin Invest. 2019;129(4):1493–1503. doi: 10.1172/JCI124611
- Revyakina VA, Ivanova EV, Kuvshinova ED, Larkova IA. Influence of family psychological factors on the course of atopic dermatitis in children. Pediatrics. The journal named after G.N. Speransky. 2018;97(2):38–43. (In Russ). doi: 10.24110/0031-403X-2018-97-2-38-43
- Tamrazova OB. Pathogenetic therapy of children suffering from severe forms of atopic dermatitis. Russian Medical Journal. Pediatrics. 2013;21(2):108–114. (In Russ).
- Larkova IA. Effective therapy of atopic dermatitis in children complicated by secondary infection. Medical advice. 2016;1:162–167. (In Russ). doi: 10.21518/2079-701X-2016-1-162-167
- Megna M, Napolitano M, Patruno C, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb). 2017;7(1):1–23. doi: 10.1007/s13555-016-0170-1
- Ilina NI, Gudima GO. Targeted therapy – the future of allergology and clinical immunology. Russian Allergological Journal. 2014;4:69–75. (In Russ).
- Simon D, Hösli S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol. 2008;121(1):122–128. doi: 10.1016/j.jaci.2007.11.016
- Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60(5):693–696. doi: 10.1111/j.1398-9995.2005.00791.x
- Vigo PG, Girgis KR, Pfuetze BL, et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 2006;55(1):168–170. doi: 10.1016/j.jaad.2005.12.045
- Ruzicka T, Hanifin JM, Furue M, et al; XCIMA Study Group. Anti-Interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376(9):826–835. doi: 10.1056/NEJMoa1606490
- Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol. 2007;120(5):1223–1225. doi: 10.1016/j.jaci.2007.08.060
- Ilina NI, Kurbacheva OM. Monoclonal antibodies in the system of anti-asthmatic treatment. Russian Allergological Journal. 2018;15(3):5–15. (In Russ).
- Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020;75(2):311–325. doi: 10.1111/all.13985
- Busse WW. Biological treatments for severe asthma: A major advance in asthma care. Allergol Int. 2019;68(2):158–166. doi: 10.1016/j.alit.2019.01.004
- Muraro A, Lemanske RF, Hellings PW, et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016;137(5):1347–1358. doi: 10.1016/j.jaci.2016.03.010
- Akdis M, Aab A, Altunbulakli C, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016;138(4):984–1010. doi: 10.1016/j.jaci.2016.06.033
- Sugita K, Steer CA, Martinez-Gonzalez I, et al. Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. J Allergy Clin Immunol. 2018;141(1):300–310.e11. doi: 10.1016/j.jaci.2017.02.038
- Sugita K, Altunbulakli C, Morita H, et al. Human type 2 innate lymphoid cells disrupt skin keratinocyte tight junction barrier by IL-13. Allergy. 2019;74(12):2534–2537. doi: 10.1111/all.13935
- Xiong Y, Cui X, Li W, et al. BLT1 signaling in epithelial cells mediates allergic sensitization via promotion of IL-33 production. Allergy. 2019;74(3):495–506. doi: 10.1111/all.13656
- Papadopoulos NG, Barnes P, Canonica GW, et al. The evolving algorithm of biological selection in severe asthma. Allergy. 2020;75(7):1555–1563. doi: 10.1111/all.14256
- Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582–1605. doi: 10.1111/all.14318
- Sanofi-Aventis U.S. LLC and Regeneron Pharmaceuticals Inc. Dupixent (dupilumab) injection: US prescribing information. 2019. Available from: http://www.acces sdata.fda.gov
- Shirley M. Dupilumab: first global approval. Drugs. 2017;77(10):1115–1121. doi: 10.1007/s40265-017-0768-3.